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INTRODUCTION 
Fine needle aspiration cytology 
(FNAC), a technique for obtaining 
cellular material for cytological 
examination and diagnosis using a 21-
gauge or smaller needle, is performed 
using a 5, 10, or 20ml syringe either 
freehand or using special syringe 
holders. It allows a minimally invasive, 
rapid diagnosis of tissue samples but 
does not preserve its histological 
architecture. 
Although exfoliative cytology (i.e. Pap 
smear) is universally accepted and 
used in Nigeria, aspiration cytology 
has yet to be widely accepted as a 
method of microscopic diagnosis. 
These two techniques differ in their 
aim. Exfoliative cytology is used 
primarily to detect precancerous and 
cancerous conditions that are not yet 
clinically apparent, aspiration cytology 
is used to determine the nature of 
clinically detectable tumours.  
The advantages of FNAC are 
innumerable and these include cost 
effectiveness, rapid reporting and 
bedside diagnosis, minimal physical 
and psychological discomfort, 
elimination of a two-stage procedure 
for diagnosis and treatment, active 
participation of the patient in treatment 
planning, and serving as a therapeutic 
procedure for evacuation of cystic 
lesions1,2 Unfortunately this technique 
is under-utilised in most centres in 
Nigeria, even when most of them have 
inadequate theatre facilities, limited 
operating time, and a heavy patient 
load culminating in long waiting lists for 
operative procedures such as open 
breast biopsies. This results in delay in 
definitive diagnosis of lesions and 
institution of appropriate early 
management, thus leading to 
increased morbidity and mortality rates 
in these patients3. Yet this rather 
simple and inexpensive diagnostic 
technique has been in use in other 
parts of the world since the 1920s-
eighty years ago! 
THE ORIGINS OF FNAC 
The earliest report of a needle 
technique being employed to obtain 
material for microscopy was by Kun in 
1847 who described a “new instrument 
for the diagnosis of tumours”. There 
followed sporadic reports of this 
technique, championed mostly by 
clinicians including Leydon who in 
1883 used needle aspiration to obtain 
cells to isolate pneumonic 
microorganisms and Greig and Gray 
who in1904 diagnosed 
trypanosomiasis in  cervical lymph 
node aspirates from patients with 
sleeping sickness in Uganda4,. Their 
findings were reported by a captain 
Bruce (later of Brucellosis fame) in a 
British Medical Journal memorandum 
in 1904. Afterwards there were other 
reports of a similar technique to 
puncture and diagnose lymph nodes 
infected by Leishmaniasis and 
secondary syphilis5. 
In the mid-1920s there were attempts 
in New York and Chicago to employ 
large needle (1.2-3.0mm) aspiration for 
a variety of sites ranging through 
lymph nodes, prostate and breast but 
over time the dimension of 1mm or 
less has come to be accepted as the 
definition of ‘thin’ or ‘fine’5,6. 
A detailed and systematic study on 
FNAC was carried out in the late 
1920s by Hayes Martin, a head and 
neck surgeon and James Ewing, the 
chief pathologist at the New York 
Memorial Hospital. Their experience 
comprising 2500 tumours annually was 
documented by Fred Stewart (a 
Histopathologist) who then enunciated 
the fundamental principles regarding 
the philosophy of aspiration biopsy and 
emphasized the need for close clinical 
and pathological co-operation. 
However, full confidence in the 
procedure was never achieved and 
this period coincided with a fierce 
controversy both in Great Britain and 
the USA over the reliability and risks of 
open biopsy in surgical practice, which 
clinicians feared would increase the 
risk of tumour spread. However, as 
their fears were laid to rest, the 
popularity of needle aspiration waned 
to such an extent that by the 1960s the 
technique was all but obsolete in the 
USA7,8.  
Interest in the procedure was 
resurrected by Europeans in the mid 
1950s. In contrast to Martin and 
Stewart who used thicker calibre (18 
gauge) needles, the European workers 
popularized the technique employing 
thin needles (22 gauge and higher) 
with an external diameter of 0.6mm or 
less. This is the technique known 
today as the fine needle aspiration 
(FNA) cytology. Developments in 
Stockholm Karolinska Radiumhemmet 
Hospital in Sweden were of utmost 
and fundamental importance. Here, 
workers such as Sixten, Franzen, 
Sordenstrom, and Torsten Lowhagen 
in collaboration with Joseph Zajicek 
applied the requisite scientific rigour to 
define precise diagnostic criteria in a 
variety of conditions. The sheer 
volume, histopathological correlation, 
follow-up information, coupled with 
superbly illustrated publications 
provided an ethos within the medical 
profession to allow the technique free 
reign. Their practice invented a novel 
specialty of ‘clinical cytologist’ who 
would examine the patient, aspirate 
the lesion, prepare and read the slide 
and arrange subsequent onward 
referral. They thus provided a model 
for FNA services for the rest of the 





 Thanks to radiological guidance, there 
is practically no organ or structure that 
is now beyond the reach of the FNAC 
needle. Masses of deep intra-
abdominal organs like the pancreas, 
kidneys, Para-aortic lymph nodes and 
also lung tumours are all subject to 
FNA cytodiagnosis. 
Without image guidance, FNACs of 
superficial masses of the breast, 
superficial lymph nodes, thyroid gland, 
salivary glands and cutaneous 
swellings are done. 
The technique can be  
• Diagnostic or 
• Therapeutic e.g. evacuation of 
benign breast cysts 
The major indication for FNA relates to 
diagnosis of either primary malignancy 
or metastatic disease. As a diagnostic 
tool for evaluating potentially malignant 
conditions FNAC has the following 
indications 
• Initial evaluation before 
treatment and in prognostication 
• Evaluation of recurrence 
following therapy 
• Evaluation of metastasis 
 
BENEFITS OF FNAC 
It is now generally agreed among 
medical professionals that FNAC 
should be the initial diagnostic 
procedure for palpable breast lesions. 
The advantages of FNAC include 
• Cost effectiveness ( simple and 
cheap) 
• It has lower risk than surgical 
biopsy 
• It is readily repeatable and 
useful for multifocal lesions 
• Minimal physical and 
psychological discomfort for the 
patient. 
• Rapid reporting and bedside 
diagnosis of neoplastic, 
hyperplastic, and inflammatory 
masses. 
• Active participation of the 
patient in treatment planning 
and provides opportunity for 
fuller preoperative counselling. 
• Elimination of a two stage 
procedure. 
• Therapeutic procedure for the 
evacuation of cystic lesions. 
• Allows cases to be prioritized 
when there is a waiting time for 
surgery 
• Permits the diagnosis of some 
benign conditions for which 
there is no need for surgery. 
• Renders unnecessary the need 
for excision biopsy in advanced 
disease, elderly patients, or in 
cases where the treatment is 
non-surgical, e.g. in 
neoadjuvant chemotherapy. 
• It is a rapid means of 
confirmation of recurrence of 




• Sampling is scanty and 
histological architecture is lost 
thereby rendering impossible 
diagnosis based on histology 
• Inflammatory, metaplastic or 
degenerative lesions may mimic 
malignancy 
• Diagnosis is indefinite in some 
conditions such as follicular 
adenoma vs. carcinoma of the 
thyroid 
• Samples taken may not be 
representative of the lesion 
• Difficulty of cytological 
diagnosis in some conditions 
e.g. lymphomas9  
 
 COMPLICATIONS 
Complications are few and seldom 
serious. The incidence of major 
complications reported is well below 
1% and generally in the range of 
0.05%5. Serious complications include: 
 
1. HAEMORRHAGE 
Serious haemorrhages have only been 
reported after FNA of deep structures 
such as the lung, liver, and kidney. 
Bleeding from CT scan-guided FNA of 
retroperitoneal adenopathy is reported 
at less than 1% despite the proximity 
to great vessels.5 
Haematoma formation is unpredictable 
but can be minimized by prolonged 
pressure following aspiration, but 
sometimes the bleeding occurs very 
rapidly even before the needle is 
withdrawn. This can obscure the lesion 
and make a second aspiration difficult 
or impossible. It may render 
mammograms difficult to interpret for 
the following two weeks; hence it is 
recommended that all imaging 
investigations should be completed 
before FNA 
 
2. PNEUMOTHORAX:  
This is a rare complication found 
mainly in women with small breasts, in 
medial lesions or when sampling 
axillary lymph nodes. Large 
pneumothoraces are obvious, but 
small ones may go undetected. Clues 
such as sharp pain, coughing, or a 
hiss of air on withdrawing the needle 
without evidence of air in the syringe 
may occur.10 
 
3. VASOVAGAL REACTIONS 
These range in severity from mild light-
headedness to syncope.  
 
4. SEEDING OF TUMOUR 
Despite the persistent fears of 
clinicians that ‘needling’ a malignancy 
may result in dissemination, there is no 




 This is common on FNA but is 
transitory and is not usually severe. 
Aspiration from painful areas of benign 
breast change is sometimes 
associated with some pain. 
Carcinomas, particularly those with 
abundant fibroelastotic stroma, are 
often painful and this can be a guide to 
the aspirator that the needle has hit 
the lesion. 
 
PITFALLS IN FNAC 
Pitfalls are common in all aspects of 
diagnostic FNAC. There are many 
different kinds of pitfalls and they occur 
in many different contexts. Some 
pitfalls are the result of factors related 
to the sampling procedure. Others are 
created by unusual microarchitectural 
features or by the appearance of the 
cellular or stromal components specific 
to the lesion being investigated. 9,12 
Errors in diagnosis of lesions can lead 
to over-treatment or delay in diagnosis 
and treatment. Aspiration cytology 
requires highly skilled and trained 
personnel in both aspiration and 
assessment. Stewart commented in 
1933 that “until the pathologist has 
familiarized himself with the various 
pitfalls, errors are certain to occur” and 
“it must not be inferred that the 
diagnosis is always simple and that no 
errors have been made”7. For this 
reason, FNAC must always be 
interpreted in association with clinical 
and radiological opinions in the triple 
approach. The NHSBSP Cytology 
Guidelines also state that “under no 
circumstances should a cytological 
opinion of malignancy in the absence 
of mammographic and / or clinical 
evidence of malignancy be taken as 
authority for therapeutic surgery”13.  
Lack of or misleading clinical 
information, non-representative 
samples, contamination of samples by 
tissue adjacent to the target lesion, 
artefacts caused by poor processing of 
samples and too much reliance on and 
technical failure of ancillary tests are 
all ‘extrinsic’ factors which can 
contribute to diagnostic errors in the 
interpretation in either of FNAC 
samples9.  
‘Intrinsic’ factors which can lead to 
diagnostic pitfalls result in false 
positive or false negative diagnosis 
arise mainly due to deviations from 
general cytodiagnostic criteria which 
can occur in a variety of non-
neoplastic and neoplastic lesions in 
different sites. The deviations may 
concern the microarchitectural pattern, 
the cellular composition or the stromal 
component of the target tissue. 
Pitfalls are an inseparable part of the 
practice of FNAC, but its occurrence 
can be minimized if the requisite 
diagnostic rigours are applied and care 
taken to correlate cytology with clinical 
history and with clinical and 
radiological findings. Multiple sampling 
used liberally when indicated, 
independent double checking by two 
pathologists of all primary malignant 
diagnoses and most importantly 
experience acquired from frequent 
usage of this technique help to 
minimize the incidence of diagnostic 




FNAC IN UBTH 
The popularity of FNAC in UBTH has 
been on the increase since the 
procedure was introduced to the 
hospital in the early 2000s. But it was 
been used rather sparingly as attested 
to by the fact that for the whole of the 
year 2003 only 5 FNACs were 
performed (all for breast masses). 
Most of which were for cases that were 
obviously clinically malignant. The 
surgeons were in these cases, for 
medico-legal reasons, looking for 
pathological justification to perform 
therapeutic surgery without necessarily 
subjecting the patient to two surgeries. 
The reasons for this initial apathy are 
manifold but were mostly centred on 
the reliability of the test result, the 
added cost implication to the patients 
and the timeliness of the result. After 
some of these fears and reservations 
were allayed, the procedure has 
gained currency among surgeons in 
UBTH to the extent that in the year 
2005 the number of FNAC done for 
breast masses alone had risen to 103. 
This has led to the setting up of a 
dedicated FNAC clinic in the 
department of pathology. In addition to 
breast lumps, other sites frequently  
aspirated in the clinic includes 
superficial lymph node enlargement, 
thyroid gland masses and salivary 
gland masses. 
In breast aspirates, where the most 
experience has been acquired over the 
past 3-4 years, we have been able to 
demonstrate that our results are most 
reliable. In the period between January 
2005 and March 2006 absolute and 
complete sensitivity of 84.6% and 
97.4% respectively were achieved. 
The specificity was 64%, positive 
predictive value for malignancies was 
100%, and there was an inadequate 
rate of 19.4%.15  
These results are comparable to those 
obtained from other centres in Nigeria 
and abroad and well above the 
minimum standard of practice 
recommended by the National Health 
Service Breast Screening Programme 
(NHSBSP) guidelines of the United 
Kingdom. 
Photomicrograph of a malignant breast smear done at the FNAC clinic in UBTH. (Haematoxylin & Eosin X40). 
In conclusion, it should be said that FNA 
technique is simple but not banal. It 
requires a certain manual dexterity in 
the same way as surgical procedures 
do. Though it has now been established 
as the first line investigation of mass 
lesions wherever they occur in the body, 
it will continue to flourish only if used 
judiciously with realistic approach of 
what is achievable kept in view and 
clear communication between clinician 
and cytopathologist maintained. 
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